GLP1R and type 1 diabetes mellitus: Specifically, overweight and obese individuals with T1D seem to be appropriate candidates to receive adjunct GLP1-RA therapy, which seem to exert their effects via the inhibition of glucagon secretion or, if still present, also via residual beta-cell function.